Market research
GMDA Gamida Cell Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 1.03
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011552663
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 1.03
About
About Gamida Cell Ltd
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GMDA discussion.
5 years, 4 months ago
Gamida Cell Ltd is currently in a long term downtrend where the price is trading 19.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Gamida Cell Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 119.5% to $-32M since the same quarter in the previous year.
Finally, its free cash flow fell by 27.3% to $-16M since the same quarter in the previous year.
Based on the above factors, Gamida Cell Ltd gets an overall score of 1/5.